Journal of Neurology

, Volume 254, Issue 2, pp 160–168

Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF

  • Jens Kuhle
  • Raija L.P. Lindberg
  • Axel Regeniter
  • Matthias Mehling
  • Francine Hoffmann
  • Markus Reindl
  • Thomas Berger
  • Ernst W. Radue
  • David Leppert
  • Ludwig Kappos
ORIGINAL COMMUNICATION

Abstract

Objective

We investigated the correlation of anti-myelin oligodendrocyte glycoprotein- (anti-MOG) and anti-myelin basic protein antibodies (anti-MBP) in serum of CIS patients with inflammatory signs in MRI and in CSF and, as previously suggested, the incidence of more frequent and rapid progression to clinically definite MS (CDMS).

Methods

133 CIS patients were analysed for anti-MOG and anti-MBP (Western blot). Routine CSF and cranial MRI (quantitatively and qualitatively) measures were analyzed. 55 patients had a follow-up of at least 12 months or until conversion to CDMS.

Results

Patients with anti-MOG and anti-MBP had an increased intrathecal IgG production and CSF white blood cell count (p = 0.048 and p = 0.036). When anti-MBP alone, or both antibodies were present the cranial MRI showed significantly more T2 lesions (p = 0.007 and p = 0.01, respectively). There was a trend for more lesion dissemination in anti-MBP positive patients (p = 0.076). Conversely, anti-MOG- and/or anti-MBP failed to predict conversion to CDMS in our follow-up group (n = 55). Only in female patients with at least one MRI lesion (n = 34) did the presence of anti-MOG correlate with more frequent (p = 0.028) and more rapid (p = 0.0209) transition to CDMS.

Conclusions

Presence of anti-MOG or anti-MBP or both was not significantly associated with conversion to CDMS in our CIS cohort. However, patients with anti-MOG and anti-MBP had higher lesion load and more disseminated lesions in cranial MRI as well as higher values for CSF leucocytes and intrathecal IgG production. Our data support a correlation of anti-MOG and anti-MBP to inflammatory signs in MRI and CSF. The prognostic value of these antibodies for CDMS, however, seems to be less pronounced than previously reported.

Keywords

clinically isolated syndrome prognosis multiple sclerosis antimyelin antibodies 

Reference

  1. 1.
    Achiron A, Barak Y (2000) Multiple sclerosis-from probable to definite diagnosis: a 7-year prospective study. Arch Neurol 57:974–979PubMedCrossRefGoogle Scholar
  2. 2.
    Andersson M, varez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Gronning M (1994) Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 57:897–902PubMedGoogle Scholar
  3. 3.
    Baumann N, Pham-Dinh D (2001) Biology of Oligodendrocyte and Myelin in the Mammalian Central Nervous System. Physiol Rev 81:871–927PubMedGoogle Scholar
  4. 4.
    Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349:139–145PubMedCrossRefGoogle Scholar
  5. 5.
    Bonifacio E, Lampasona V, Bingley PJ (1998) IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol 161:2648–2654PubMedGoogle Scholar
  6. 6.
    Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158–164PubMedCrossRefGoogle Scholar
  7. 7.
    Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C (1989) Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats. J Neurochem 52:296–304PubMedCrossRefGoogle Scholar
  8. 8.
    Cepok S, Jacobsen M, Schock S, Omer B, Jaekel S, Boddeker I, Oertel WH, Sommer N, Hemmer B (2001) Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 124:2169–2176PubMedCrossRefGoogle Scholar
  9. 9.
    Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576–1582PubMedCrossRefGoogle Scholar
  10. 10.
    Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770–782PubMedCrossRefGoogle Scholar
  11. 11.
    Egg R, Reindl M, Deisenhammer F, Linington C, Berger T (2001) Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler 7:285–289PubMedGoogle Scholar
  12. 12.
    Eriksson M, Andersen O, Runmarker B (2003) Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 9:260–274PubMedCrossRefGoogle Scholar
  13. 13.
    Farlow MR, Edwards MK, Kolar OJ, Stevens JC, Yu PL (1987) Magnetic resonance imaging in multiple sclerosis: analysis of correlations to peripheral blood and spinal fluid abnormalities. Neurology 37:1527–1530PubMedGoogle Scholar
  14. 14.
    Frederiksen JL, Larsson HB, Olesen J (1992) Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis. Acta Neurol Scand 86:317–322PubMedGoogle Scholar
  15. 15.
    Gaertner S, de Graaf KL, Greve B, Weissert R (2004) Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 63:2381–2383PubMedGoogle Scholar
  16. 16.
    Galboiz Y, Miller A (2002) Immunological indicators of disease activity and prognosis in multiple sclerosis. Curr Opin Neurol 15:233–237PubMedCrossRefGoogle Scholar
  17. 17.
    Genain CP, Cannella B, Hauser SL, Raine CS (1999) Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5:170–175PubMedCrossRefGoogle Scholar
  18. 18.
    Genain CP, Nguyen MH, Letvin NL, Pearl R, Davis RL, Adelman M, Lees MB, Linington C, Hauser SL (1995) Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 96:2966–2974PubMedCrossRefGoogle Scholar
  19. 19.
    Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904PubMedCrossRefGoogle Scholar
  20. 19a.
    Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R, for the BENEFIT Study Group (2006) Treatment with interferon beta 1–6 delays conversion to clinically definite and McDonald Ms in patients with clinically isolated syndromes. Neurology 67:1242–1249PubMedCrossRefGoogle Scholar
  21. 20.
    Keir G, Luxton RW, Thompson EJ (1990) Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update. Ann Clin Biochem 27 (Pt 5):436–443PubMedGoogle Scholar
  22. 21.
    Kerlero de RN, Honegger P, Lassmann H, Matthieu JM (1990) Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein. J Neurochem 55:583–587CrossRefGoogle Scholar
  23. 22.
    Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL (1977) Studies on the natural history of multiple sclerosis–8. Early prognostic features of the later course of the illness. J Chronic Dis 30:819–830PubMedCrossRefGoogle Scholar
  24. 23.
    Lampasona V, Franciotta D, Furlan R, Zanaboni S, Fazio R, Bonifacio E, Comi G, Martino G (2004) Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 62:2092–2094PubMedGoogle Scholar
  25. 24.
    Lee KH, Hashimoto SA, Hooge JP, Kastrukoff LF, Oger JJ, Li DK, Paty DW (1991) Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 41:657–660PubMedGoogle Scholar
  26. 25.
    Lim ET, Berger T, Reindl M, Dalton CM, Fernando K, Keir G, Thompson EJ, Miller DH, Giovannoni G (2005) Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Multi Scler 11:492–494CrossRefGoogle Scholar
  27. 26.
    Linington C, Bradl M, Lassmann H, Brunner C, Vass K (1988) Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130:443–454PubMedGoogle Scholar
  28. 27.
    Link H, Tibbling G (1977) Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 37:397–401PubMedGoogle Scholar
  29. 28.
    Linnington C, Webb M, Woodhams PL (1984) A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J Neuroimmunol 6:387–396PubMedCrossRefGoogle Scholar
  30. 29.
    Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6:259–274PubMedGoogle Scholar
  31. 30.
    Miller DH, Ormerod IE, Gibson A, du Boulay EP, Rudge P, McDonald WI (1987) MR brain scanning in patients with vasculitis: differentiation from multiple sclerosis. Neuroradiology 29:226–231PubMedCrossRefGoogle Scholar
  32. 31.
    Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, MacManus DG, McDonald WI (1993) The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116 (Pt 1):135–146PubMedCrossRefGoogle Scholar
  33. 32.
    O’Connor KC, Chitnis T, Griffin DE, Piyasirisilp S, Bar-Or A, Khoury S, Wucherpfennig KW, Hafler DA (2003) Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol 136:140–14833PubMedCrossRefGoogle Scholar
  34. 33.
    Olsson T (1994) Multiple sclerosis:cerebrospinal fluid. Ann Neurol 36 Suppl:S100–S102PubMedCrossRefGoogle Scholar
  35. 34.
    Ormerod IE, Bronstein A, Rudge P, Johnson G, Macmanus D, Halliday AM, Barratt H, Du Boulay EP, Kendal BE, Moseley IF, . (1986) Magnetic resonance imaging in clinically isolated lesions of the brain stem. J Neurol Neurosurg Psychiatry 49:737–743PubMedCrossRefGoogle Scholar
  36. 35.
    Pagany M, Jagodic M, Schubart A, Pham-Dinh D, Bachelin C, Baron van EA, Lachapelle F, Olsson T, Linington C (2003) Myelin oligodendrocyte glycoprotein is expressed in the peripheral nervous system of rodents and primates. Neurosci Lett 350:165–168PubMedCrossRefGoogle Scholar
  37. 36.
    Reiber H (1994) Flow rate of cerebrospinal fluid (CSF)–a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases [see comments]. J Neurol Sci 122:189–203PubMedCrossRefGoogle Scholar
  38. 37.
    Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, Poewe W, Berger T (1999) Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 122 (Pt 11):2047–2056PubMedCrossRefGoogle Scholar
  39. 38.
    Schluesener HJ, Sobel RA, Linington C, Weiner HL (1987) A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 139:4016–4021PubMedGoogle Scholar
  40. 39.
    Sharief MK, Thompson EJ (1991) The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. Ann Neurol 29:147–151PubMedCrossRefGoogle Scholar
  41. 40.
    Stefferl A, Brehm U, Linington C (2000) The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neural Transm Suppl 123–133Google Scholar
  42. 41.
    Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, Olsson T, Linington C, Lassmann H (1998) Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8:681–694PubMedCrossRefGoogle Scholar
  43. 42.
    Sun J, Link H, Olsson T, Xiao BG, Andersson G, Ekre HP, Linington C, Diener P (1991) T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 146:1490–1495PubMedGoogle Scholar
  44. 43.
    Uitdehaag BM, Kappos L, Bauer L, Freedman MS, Miller D, Sandbrink R, Polman C (2005) Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Multi Scler 11:227–231CrossRefGoogle Scholar
  45. 44.
    Villoslada P, Abel K, Heald N, Goertsches R, Hauser SL, Genain CP (2001) Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates. Eur J Immunol 31:2942–2950PubMedCrossRefGoogle Scholar
  46. 45.
    Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112 (Pt 6):1419–1428PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2007

Authors and Affiliations

  • Jens Kuhle
    • 1
    • 2
  • Raija L.P. Lindberg
    • 1
    • 2
  • Axel Regeniter
    • 3
  • Matthias Mehling
    • 1
    • 2
  • Francine Hoffmann
    • 1
    • 2
  • Markus Reindl
    • 5
  • Thomas Berger
    • 5
  • Ernst W. Radue
    • 4
  • David Leppert
    • 1
    • 2
    • 6
  • Ludwig Kappos
    • 1
    • 2
    • 7
  1. 1.Dept. of NeurologyUniversity Hospital BaselBaselSwitzerland
  2. 2.Clinical Neuroimmunology Laboratory, Dept. of ResearchUniversity Hospital BaselBaselSwitzerland
  3. 3.Clinical Chemistry LaboratoryUniversity Hospital BaselBaselSwitzerland
  4. 4.Dept. of NeuroradiologyUniversity Hospital BaselBaselSwitzerland
  5. 5.Clinical Dept. of NeurologyInnsbruck Medical UniversityInnsbruckAustria
  6. 6.Biomarker and Experimental Medicine UnitsAddenbroke’s Centre for Clinical Investigation, GlaxoSmithKline R & DCambridgeGreat Britain
  7. 7.Head Outpatients Clinics Neurology and NeurosurgeryUniversity Hospital BaselBaselSwitzerland

Personalised recommendations